Table 1.
HLA-A Second Allele Frequencies in the French Cohort Compared to UKB and GHS EUR A29 Carriers
| UParis (A29 EUR Carriers) | GHS Cohort 1 (A29 EUR) | GHS Cohort 2 (A29 EUR) | UKB (A29 EUR) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Second HLA-A Allele | Cases (N = 286), n (Frequency) | Controls (N = 108), n (Frequency) | OR (LCI–UCI) | P | Carriers (N = 4014), n (Frequency) | OR (LCI–UCI) | P | Carriers (N = 2829), n (Frequency) | OR (LCI–UCI) | P | Carriers (N = 38,543), n (Frequency) | OR (LCI–UCI) | P |
| Aw19 co-susceptible (29, 30, 31, 33) | 41 (0.14) | 4 (0.04) | 4.44 (1.55–17.53) | 2.20E-03 | 247 (0.06) | 2.63 (1.80–3.78) | 1.29E-06 | 164 (0.06) | 2.69 (1.81–3.92) | 1.07E-06 | 2416 (0.06) | 2.51 (1.75–3.52) | 9.62E-07 |
| A3002 | 13 (0.05) | 1 (0.01) | 5.19 (0.76–222.84) | 0.12 | 45 (0.01) | 4.31 (2.11–8.26) | 6.15E-05 | 20 (0.01) | 6.60 (2.98–14.13) | 3.03E-06 | 396 (0.01) | 4.60 (2.39–8.09) | 1.25E-05 |
| A3301 | 9 (0.03) | 0 (0.00) | Infinite (0.77–infinity) | 0.07 | 39 (0.01) | 3.40 (1.43–7.23) | 3.20E-03 | 32 (0.01) | 2.80 (1.16–6.09) | 0.01 | 255 (0.01) | 4.89 (2.19–9.56) | 1.63E-04 |
| A0301 | 26 (0.09) | 15 (0.14) | 0.63 (0.31–1.35) | 0.20 | 592 (0.15) | 0.59 (0.38–0.90) | 0.01 | 380 (0.13) | 0.63 (0.40–0.97) | 0.03 | 5497 (0.14) | 0.60 (0.38–0.90) | 0.01 |
| A0101 | 71 (0.25) | 17 (0.16) | 1.81 (0.99–3.48) | 0.04 | 662 (0.16) | 1.73 (1.29–2.31) | 2.67E-04 | 448 (0.16) | 1.74 (1.28–2.33) | 3.21E-04 | 7411 (0.19) | 1.39 (1.05–1.83) | 0.02 |
| A3201 | 3 (0.01) | 4 (0.04) | 0.28 (0.04–1.70) | 0.10 | 152 (0.04) | 0.28 (0.06–0.83) | 0.01 | 105 (0.04) | 0.27 (0.05–0.82) | 0.02 | 1323 (0.03) | 0.30 (0.06–0.88) | 0.02 |
| A0201 | 64 (0.22) | 24 (0.22) | 1.03 (0.59–1.85) | 1.00 | 1085 (0.27) | 0.80 (0.59–1.08) | 0.14 | 756 (0.27) | 0.78 (0.57–1.04) | 0.09 | 10680 (0.28) | 0.75 (0.56–1.00) | 0.05 |
| A2902 | 10 (0.03) | 1 (0.01) | 3.95 (0.55–173.12) | 0.30 | 48 (0.01) | 3.07 (1.37–6.24) | 3.65E-03 | 37 (0.01) | 2.70 (1.18–5.61) | 9.43E-03 | 750 (0.02) | 1.83 (0.86–3.43) | 0.08 |
| A2601 | 8 (0.03) | 3 (0.03) | 1.03 (0.24–6.13) | 1.00 | 115 (0.03) | 1.00 (0.42–2.07) | 1.00 | 91 (0.03) | 0.85 (0.35–1.78) | 0.86 | 834 (0.02) | 1.30 (0.55–2.62) | 0.41 |
| A2501 | 3 (0.01) | 2 (0.02) | 0.57 (0.06–6.96) | 0.62 | 101 (0.03) | 0.42 (0.08–1.28) | 0.16 | 47 (0.03) | 0.62 (0.12–1.94) | 0.62 | 673 (0.02) | 0.60 (0.12–1.77) | 0.50 |
| A2402 | 23 (0.08) | 11 (0.10) | 0.79 (0.35–1.86) | 0.55 | 356 (0.09) | 0.92 (0.57–1.44) | 0.83 | 249 (0.09) | 0.89 (0.55–1.40) | 0.74 | 2801 (0.07) | 1.12 (0.69–1.72) | 0.57 |
| A3101 | 9 (0.03) | 2 (0.02) | 1.75 (0.35–16.95) | 0.73 | 115 (0.03) | 1.13 (0.50–2.26) | 0.71 | 75 (0.03) | 1.18 (0.51–2.39) | 0.57 | 1015 (0.03) | 1.20 (0.54–2.33) | 0.58 |
| A1101 | 14 (0.05) | 10 (0.09) | 0.52 (0.21–1.34) | 0.16 | 255 (0.06) | 0.78 (0.41–1.36) | 0.44 | 177 (0.06) | 0.76 (0.40–1.33) | 0.44 | 2278 (0.06) | 0.82 (0.44–1.40) | 0.61 |
| A2301 | 6 (0.02) | 2 (0.02) | 1.16 (0.20–11.91) | 1.00 | 94 (0.02) | 0.92 (0.33–2.10) | 1.00 | 61 (0.02) | 0.96 (0.34–2.24) | 1.00 | 672 (0.02) | 1.21 (0.44–2.68) | 0.65 |
| A6801 | 9 (0.03) | 8 (0.07) | 0.42 (0.14–1.27) | 0.09 | 128 (0.03) | 1.01 (0.45–2.01) | 0.86 | 100 (0.04) | 0.87 (0.38–1.76) | 0.87 | 1142 (0.03) | 1.07 (0.48–2.06) | 0.86 |
| A19 all (29–33) | 44 (0.15) | 8 (0.07) | 2.07 (0.92–4.64) | 0.08 | 399 (0.10) | 1.49 (1.02–2.18) | 0.04 | 269 (0.10) | 1.58 (1.07–2.34) | 0.02 | 3739 (0.10) | 1.51 (1.04–2.18) | 0.03 |
Alleles belonging to the Aw19 broad antigen group that increase risk are A29, A30, A31, and A33; A32 exhibits protection. A Fisher's exact test combining all Aw19 risk alleles presented the strongest enrichment in all comparisons. Only alleles having three or more case carriers were tested. The table is sorted by P values when comparing case frequencies against A29 controls in the UKB.